Edwards Lifesciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EW and other ETFs, options, and stocks.

About EW

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. 

CEO
Bernard J. Zovighian
CEOBernard J. Zovighian
Employees
16,000
Employees16,000
Headquarters
Irvine, California
HeadquartersIrvine, California
Founded
1958
Founded1958
Employees
16,000
Employees16,000

EW Key Statistics

Market cap
58.56B
Market cap58.56B
Price-Earnings ratio
59.32
Price-Earnings ratio59.32
Dividend yield
—
Dividend yield—
Average volume
4.28M
Average volume4.28M
High today
$104.92
High today$104.92
Low today
$101.66
Low today$101.66
Open price
$102.95
Open price$102.95
Volume
3.32M
Volume3.32M
52 Week high
$108.00
52 Week high$108.00
52 Week low
$74.66
52 Week low$74.66

Stock Snapshot

The current Edwards Lifesciences(EW) stock price is $101.85, with a market capitalization of 58.56B. The stock trades at a price-to-earnings (P/E) ratio of 59.32.

During the trading session on 2026-11-21, Edwards Lifesciences(EW) shares reached a daily high of $104.92 and a low of $101.66. At a current price of $101.85, the stock is +0.2% higher than the low and still -2.9% under the high.

Trading activity shows a volume of 3.32M, compared to an average daily volume of 4.28M.

Over the past 52 weeks, Edwards Lifesciences(EW) stock has traded between a high of $108.00 and a low of $74.66.

Over the past 52 weeks, Edwards Lifesciences(EW) stock has traded between a high of $108.00 and a low of $74.66.

EW News

Investing.com 1d
RBC Capital reiterates Edwards Lifesciences stock rating on growth outlook - Investing.com

...

RBC Capital reiterates Edwards Lifesciences stock rating on growth outlook - Investing.com
TipRanks 1d
Edwards Lifesciences growth expected to continue, says RBC Capital

RBC Capital analyst Shagun Singh keeps an Outperform rating and $115 price target on Edwards Lifesciences (EW) ahead of its Investor Day presentation. The firm...

TipRanks 2d
Edwards Lifesciences Enters New $750 Million Revolving Credit Agreement

An announcement from Edwards Lifesciences ( (EW) ) is now available. On November 19, 2026, Edwards Lifesciences entered an amended and restated five-year credi...

Analyst ratings

81%

of 32 ratings
Buy
81.3%
Hold
15.6%
Sell
3.1%

More EW News

TipRanks 2d
Edwards’ PASCAL Valve Study Update: What EW Investors Should Know

Edwards Lifesciences Corp. (EW) announced an update on their ongoing clinical study. Study Overview: Edwards Lifesciences’ CLASP Study, officially titled The C...

TipRanks 2d
Edwards Lifesciences price target raised to $116 from $112 at Leerink

Leerink raised the firm’s price target on Edwards Lifesciences (EW) to $116 from $112 and keeps an Outperform rating on the shares. The firm has growing convict...

Simply Wall St 6d
What Edwards Lifesciences Earnings Beat Means For Shareholders

Edwards Lifesciences reported Q3 2026 sales of US$1,715.5 million and net income of US$307.5 million, raised full year guidance and outlined Q4 sales expectatio...

What Edwards Lifesciences Earnings Beat Means For Shareholders

People also own

Based on the portfolios of people who own EW. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.